(603676)"XIZANG WEIXINKANG PHARMACEUTICAL CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 603676 · · 11 pages · Chinese
Summary by 6ix AI
The report indicates a decline in both revenue and net profit compared to the same period last year, with significant decreases in key financial metrics. The company assures that the report's content is accurate and complete, and it has not been audited. Total assets have increased slightly compared to the end of the previous year, reflecting some growth despite the overall decline in profitability.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Xizang Weixinkang Pharmaceutical Co., Ltd. on 6ix
Earlier from Xizang Weixinkang Pharmaceutical
- Announcement on Receipt of the Drug Registration Certificate for Water-soluble Vitamin for Injection by a Subsidiary
- Announcement on Receipt of the Approval Notice for Supplementary Application for Potassium Aspartate Injection by a Subsidiary
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on the Subsidiary's Acquisition of the Drug Registration Certificate for Multivitamin Injection (12)
- Announcement on Participation in Subscription of Private Equity Fund Shares
Follow Xizang Weixinkang Pharmaceutical into a list and get an email when it puts out news.
Follow Xizang Weixinkang Pharmaceutical